Fujifilm announced today that it has received marketing approval in Japan for Lutathera injection for the treatment of somatostatin receptor-positive neuroendocrine tumors.

Lutathera is a peptide receptor radionuclide therapy (PRRT), a subclass of radioligand therapy (RLT). Lutathera injection is the first PRRT drug in Japan.